Evidence map›Paper›PMID 35158807›Full record

ReviewCancers2022

The Good, the Bad, and the Ugly: Neutrophils, Angiogenesis, and Cancer.

Irem Ozel, Inga Duerig, Maksim Domnich, Stephan Lang, Ekaterina Pylaeva, Jadwiga Jablonska

Open access · goldAbstract readReview
In one paragraph

Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 2 pooled it
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 2 syntheses or guidelines pooled it, 75 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Frontiers in immunology · 2026
    Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Irem OzelDepartment of Otorhinolaryngology, University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany.ORCID 0000-0002-7007-9928
Inga DuerigDepartment of Otorhinolaryngology, University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany.ORCID 0000-0001-7358-5466
Maksim DomnichDepartment of Otorhinolaryngology, University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany.ORCID 0000-0003-4954-5418
Stephan LangDepartment of Otorhinolaryngology, University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany.
Ekaterina PylaevaDepartment of Otorhinolaryngology, University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany.ORCID 0000-0002-3941-9664
Jadwiga JablonskaDepartment of Otorhinolaryngology, University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany.ORCID 0000-0003-1490-2542
University of Duisburg-Essen · DE

Funding

Deutsche Forschungsgemeinschaft DFG/ JA 2461/5-1Deutsche Forschungsgemeinschaft DFG/ JA 2461/7-1German Cancer Aid 111647
6 · The paper itself

Abstract

Angiogenesis, the formation of new blood vessels from already existing vasculature, is tightly regulated by pro- and anti-angiogenic stimuli and occurs under both physiological and pathological conditions. Tumor angiogenesis is central for tumor development, and an "angiogenic switch" could be initiated by multiple immune cells, such as neutrophils. Tumor-associated neutrophils promote tumor angiogenesis by the release of both conventional and non-conventional pro-angiogenic factors. Therefore, neutrophil-mediated tumor angiogenesis should be taken into consideration in the design of novel anti-cancer therapy. This review recapitulates the complex role of neutrophils in tumor angiogenesis and summarizes neutrophil-derived pro-angiogenic factors and mechanisms regulating angiogenic activity of tumor-associated neutrophils. Moreover, it provides up-to-date information about neutrophil-targeting therapy, complementary to anti-angiogenic treatment.

Indexed as

cancerneutrophilstumor angiogenesistumor vasculature

Identifiers

PMID35158807
PMCPMC8833332
OpenAlexW4207002960

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.